Immunic, Inc. (NASDAQ:IMUX) shares surged 20% in Friday morning trading following the announcement of a significant oversubscribed private placement. This financing deal positions the company to raise up to $400 million, capital that will directly fund its advanced development programs for multiple sclerosis (MS) treatments and facilitate its evolution into a commercial organization.

Major Institutional Backing Drives Momentum

Existing investor BVF Partners L.P. led the financing round, demonstrating continued confidence in Immunic's clinical trajectory. The deal also attracted participation from a consortium of prominent institutional investors, including Aberdeen Investments, Avidity Partners, OrbiMed, and RA Capital Management.

Under the terms of the agreement, Immunic secures $200 million in upfront proceeds immediately. Furthermore, the structure of the deal provides the potential for an additional $200 million, contingent on future milestones.

Accelerating Clinical Development

Immunic plans to deploy these funds strategically to advance its lead asset, vidofludimus calcium. specifically, the capital will support the completion of ongoing phase 3 ENSURE trials targeting relapsing multiple sclerosis (RMS). The company anticipates releasing top-line data from these trials by the end of 2026.

Beyond the RMS indication, the financing enables Immunic to expand its clinical footprint. Later this year, the company intends to initiate a phase 3 clinical program focusing on primary progressive multiple sclerosis, broadening the potential scope of its therapeutic portfolio.

Strategic Leadership Realignment

Coinciding with this financial milestone, Immunic disclosed key leadership changes designed to steer the company through its next growth phase. The Board of Directors has elevated Simona Skerjanec to the role of interim Chairperson. Skerjanec brings relevant experience to the position, having previously served as SVP and Global Head of Neuroscience and Rare Diseases at Roche.

Simultaneously, the company announced it will begin the search for a new Chief Executive Officer with specific commercial expertise. This transition sees current CEO and co-founder Dr. Daniel Vitt preparing to move into a new senior executive role, where he will continue to support the organization’s strategic objectives.

“I could not be prouder of the Immunic team and what we have achieved with vidofludimus calcium,” stated Dr. Vitt. “The proceeds from the initial closing are expected to provide sufficient runway through submission of an NDA in the United States in mid-2027 and to start preparations for the potential launch of vidofludimus calcium in RMS.”

For more investor relations information on Immunic Inc. please visit www. ir.imux.com.

The post Immunic Secures $400 Million Financing to Propel Multiple Sclerosis Programs and Commercial Transition appeared first on PRISM MarketView.

COMTEX_473458339/2927/2026-02-13T09:30:48